A Multicenter, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of RBP-7000 Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) Compared to Intermediate Molecular Weight (Reference Treatment) Polymer in Subjects With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Indivior
- 13 Jul 2016 Status changed from active, no longer recruiting to completed.
- 14 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
- 25 Feb 2016 New trial record